TY - JOUR
T1 - Effect of pharmacological interventions on lipid profiles and C-reactive protein in polycystic ovary syndrome
T2 - A systematic review and meta-analysis
AU - Abdalla, Mohammed A.
AU - Shah, Najeeb
AU - Deshmukh, Harshal
AU - Sahebkar, Amirhossein
AU - Östlundh, Linda
AU - Al-Rifai, Rami H.
AU - Atkin, Stephen L.
AU - Sathyapalan, Thozhukat
N1 - Funding Information:
We thank Dr. Gamila Hassan at the National Medical Library (UAEU) for her support with locating and uploading full-text papers to Covidence for screening. This systematic review was completed as part of a self-funded PhD project for M.A and no external fund was received.
Publisher Copyright:
© 2021 John Wiley & Sons Ltd.
PY - 2022/4
Y1 - 2022/4
N2 - Context: Polycystic ovary syndrome (PCOS) is a heterogeneous condition affecting women of reproductive age. It is associated with dyslipidaemia and elevated plasma C-reactive protein (CRP), which increase the risks of cardiovascular disease (CVD). Objective: To review the existing evidence on the effects of different pharmacological interventions on lipid profiles and CRP of women with PCOS. Data Sources: We searched PubMed, MEDLINE, Scopus, Embase, Cochrane Library, and Web of Science in April 2020 and updated the results in March 2021. Study Selection: The study included randomized controlled trials (RCTs) and follows the 2020 Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA). Data Extraction: Two independent researchers extracted data and assessed for risk of bias using the Cochrane risk of bias tool. Covidence systematic review software were used for blinded screening and study selection. Data Synthesis: In 29 RCTs, there were significant reductions in triglycerides with atorvastatin versus placebo [mean difference (MD): −0.21 mmol/L; 95% confidence interval (CI): −0.39, −0.03, I2 = 0%, moderate grade evidence]. Significant reductions were seen for low-density lipoprotein cholesterol (LDL-C) with metformin versus placebo [standardized mean difference (SMD): −0.41; 95% CI: −0.85, 0.02, I2 = 59%, low grade evidence]. Significant reductions were also seen for total cholesterol with saxagliptin versus metformin (MD: −0.15 mmol/L; 95% CI: −0.23, −0.08, I2 = 0%, very low grade evidence). Significant reductions in C-reactive protein (CRP) were seen for atorvastatin versus placebo (MD: −1.51 mmol/L; 95% CI: −3.26 to 0.24, I2 = 75%, very low-grade evidence). Conclusion: There were significant reductions in the lipid parameters when metformin, atorvastatin, saxagliptin, rosiglitazone and pioglitazone were compared with placebo or other agents. There was also a significant reduction of CRP with atorvastatin.
AB - Context: Polycystic ovary syndrome (PCOS) is a heterogeneous condition affecting women of reproductive age. It is associated with dyslipidaemia and elevated plasma C-reactive protein (CRP), which increase the risks of cardiovascular disease (CVD). Objective: To review the existing evidence on the effects of different pharmacological interventions on lipid profiles and CRP of women with PCOS. Data Sources: We searched PubMed, MEDLINE, Scopus, Embase, Cochrane Library, and Web of Science in April 2020 and updated the results in March 2021. Study Selection: The study included randomized controlled trials (RCTs) and follows the 2020 Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA). Data Extraction: Two independent researchers extracted data and assessed for risk of bias using the Cochrane risk of bias tool. Covidence systematic review software were used for blinded screening and study selection. Data Synthesis: In 29 RCTs, there were significant reductions in triglycerides with atorvastatin versus placebo [mean difference (MD): −0.21 mmol/L; 95% confidence interval (CI): −0.39, −0.03, I2 = 0%, moderate grade evidence]. Significant reductions were seen for low-density lipoprotein cholesterol (LDL-C) with metformin versus placebo [standardized mean difference (SMD): −0.41; 95% CI: −0.85, 0.02, I2 = 59%, low grade evidence]. Significant reductions were also seen for total cholesterol with saxagliptin versus metformin (MD: −0.15 mmol/L; 95% CI: −0.23, −0.08, I2 = 0%, very low grade evidence). Significant reductions in C-reactive protein (CRP) were seen for atorvastatin versus placebo (MD: −1.51 mmol/L; 95% CI: −3.26 to 0.24, I2 = 75%, very low-grade evidence). Conclusion: There were significant reductions in the lipid parameters when metformin, atorvastatin, saxagliptin, rosiglitazone and pioglitazone were compared with placebo or other agents. There was also a significant reduction of CRP with atorvastatin.
KW - HDL
KW - LDL
KW - pharmacological therapy
KW - polycystic ovary syndrome (PCOS)
KW - therapeutic agents
KW - total cholesterol
KW - triglycerides
UR - http://www.scopus.com/inward/record.url?scp=85119261400&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119261400&partnerID=8YFLogxK
U2 - 10.1111/cen.14636
DO - 10.1111/cen.14636
M3 - Review article
C2 - 34779013
AN - SCOPUS:85119261400
SN - 0300-0664
VL - 96
SP - 443
EP - 459
JO - Clinical Endocrinology
JF - Clinical Endocrinology
IS - 4
ER -